These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. Zhu J; Huang X; Yang Y J Virol; 2007 Apr; 81(7):3170-80. PubMed ID: 17229689 [TBL] [Abstract][Full Text] [Related]
5. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. Abbink P; Lemckert AA; Ewald BA; Lynch DM; Denholtz M; Smits S; Holterman L; Damen I; Vogels R; Thorner AR; O'Brien KL; Carville A; Mansfield KG; Goudsmit J; Havenga MJ; Barouch DH J Virol; 2007 May; 81(9):4654-63. PubMed ID: 17329340 [TBL] [Abstract][Full Text] [Related]
6. NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo. Suzuki M; Cela R; Bertin TK; Sule G; Cerullo V; Rodgers JR; Lee B Hum Gene Ther; 2011 Sep; 22(9):1071-82. PubMed ID: 21561248 [TBL] [Abstract][Full Text] [Related]
7. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. Liu J; Ewald BA; Lynch DM; Denholtz M; Abbink P; Lemckert AA; Carville A; Mansfield KG; Havenga MJ; Goudsmit J; Barouch DH J Virol; 2008 May; 82(10):4844-52. PubMed ID: 18337575 [TBL] [Abstract][Full Text] [Related]
8. The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector. Lebedeva E; Bagaev A; Pichugin A; Chulkina M; Lysenko A; Tutykhina I; Shmarov M; Logunov D; Naroditsky B; Ataullakhanov R BMC Immunol; 2018 Jul; 19(1):26. PubMed ID: 30055563 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931 [TBL] [Abstract][Full Text] [Related]
10. CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. Lindsay RW; Darrah PA; Quinn KM; Wille-Reece U; Mattei LM; Iwasaki A; Kasturi SP; Pulendran B; Gall JG; Spies AG; Seder RA J Immunol; 2010 Aug; 185(3):1513-21. PubMed ID: 20610651 [TBL] [Abstract][Full Text] [Related]
11. Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine. Zhang Y; Feng L; Li L; Wang D; Li C; Sun C; Li P; Zheng X; Liu Y; Yang W; Niu X; Zhong N; Chen L Hum Vaccin Immunother; 2015; 11(7):1803-13. PubMed ID: 26076321 [TBL] [Abstract][Full Text] [Related]
12. The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. Dicks MD; Guzman E; Spencer AJ; Gilbert SC; Charleston B; Hill AV; Cottingham MG Vaccine; 2015 Feb; 33(9):1121-8. PubMed ID: 25629523 [TBL] [Abstract][Full Text] [Related]
13. Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine. Choi JH; Schafer SC; Freiberg AN; Croyle MA Mol Pharm; 2015 Aug; 12(8):2697-711. PubMed ID: 25549696 [TBL] [Abstract][Full Text] [Related]
14. Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors. Yamaguchi T; Kawabata K; Koizumi N; Sakurai F; Nakashima K; Sakurai H; Sasaki T; Okada N; Yamanishi K; Mizuguchi H Hum Gene Ther; 2007 Aug; 18(8):753-62. PubMed ID: 17685831 [TBL] [Abstract][Full Text] [Related]
15. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. Wang J; Thorson L; Stokes RW; Santosuosso M; Huygen K; Zganiacz A; Hitt M; Xing Z J Immunol; 2004 Nov; 173(10):6357-65. PubMed ID: 15528375 [TBL] [Abstract][Full Text] [Related]
16. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039 [TBL] [Abstract][Full Text] [Related]
17. Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys. Sun Y; Bailer RT; Rao SS; Mascola JR; Nabel GJ; Koup RA; Letvin NL J Virol; 2009 Oct; 83(20):10596-604. PubMed ID: 19656883 [TBL] [Abstract][Full Text] [Related]
19. Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Hartman ZC; Osada T; Glass O; Yang XY; Lei GJ; Lyerly HK; Clay TM Cancer Res; 2010 Sep; 70(18):7209-20. PubMed ID: 20823152 [TBL] [Abstract][Full Text] [Related]
20. Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery. Kaulfuß M; Wensing I; Windmann S; Hrycak CP; Bayer W Retrovirology; 2017 Feb; 14(1):8. PubMed ID: 28166802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]